R-Concept has been acquired by BioScientific Group
The shareholders of R-Concept have sold the company to BioScientific Group.
R-Concept is a Belgian company active in the production of stainless steel equipment, mechanical and electromechanical pieces and clean piping solutions. The company has been active for more than 10 years and works with the pharmaceutical (mainly), food, petrochemical and hospital sectors in Belgium. Its main clients include GSK, UCB, Pfizer and Takeda.
BioScientific Group is a Belgium-based holding company active in the design, production, installation and maintenance of clean piping, air processing, HVAC and tailor-made stainless steel equipment.
Oaklins’ team in Belgium acted as financial advisor to the sellers in this transaction.



Jamel Jellouli
CEO and Founder, R-Concept
Talk to the deal team
Philippe Desomberg
Oaklins KBC Securities
Related deals
East Metal has been acquired by management and private investors
The Latvia-based metalworking company East Metal has been acquired from its former Danish owner, East Metal Holding, through a management buy-out (MBO) by a group of private investors, the current owners of Valpro, in partnership with the local management team. Financing for the transaction was provided by Signet Bank.
Learn moreQuantum Base Holdings plc has completed its official admission to AIM
Quantum Base began trading on the London Stock Exchange’s AIM market under the ticker QUBE following a US$6.4 million (£4.8 million) fundraising round. The company develops Q-ID tags, a quantum-based authentication technology designed to prevent counterfeiting by leveraging atomic-level randomness. Proceeds from the listing will fund product development and commercial expansion, including new operational and commercial hires.
Learn moreDoosan Skoda Power has been listed on the Prague Stock Exchange with a US$104 million initial public offering
Doosan Skoda Power and its parent company, Doosan Power Systems, have placed just over US$114 million (€100 million) of the company’s shares, of which US$31.4 million (€27.6 million) supported a 10% capital increase and US$72.4 million (€63.7 million), representing 23% of the pre-transaction share capital, was returned to the selling shareholder. This amount includes US$10.5 million (€9.2 million) in greenshoe shares, equivalent to 10% of the base deal.
Learn more